Nivolumab is already approved for use in cases of melanoma, renal cancer, Hodgkin lymphoma and a form of cancer affecting the head and neck, and has now been approved for lung cancer.

The Health Service Executive (HSE) has recommended the use of the potentially life-extending cancer drug nivolumab (sold as Opdivo) for patients with (...)